Depression Symptoms Predict Worse Clinical Response to Etanercept Treatment in Psoriasis Patients
Authors:
- 8 November 2018
- journal article
- research article
- Published by S. Karger AG in Dermatology
- Vol. 235 (1) , 55-64
Abstract
Background/Aims: This study aimed to investigate the predicting values of depression and anxiety symptoms for clinical response to etanercept treatment in psoriasis patients. Methods: A total of 85 psoriasis patients who received 6 months of etanercept treatment were consecutively enrolled in this prospective cohort study. The Psoriasis Area and Severity Index (PASI) score was evaluated at month 0 (M0), M1, M3, and M6, and the corresponding PASI 75/90 response at each visit was assessed. Also, anxiety and depression symptoms were assessed by the Hospital Anxiety and Depression Scale (HADS) at M0, M1, M3, and M6. Results: Depression symptoms were observed to correlate with female gender (p = 0.004), longer disease duration (p = 0.018), and higher PASI score (p < 0.001), and anxiety symptoms were seen to be associated with female gender (p = 0.017), larger psoriasis-affected body surface area (p = 0.049), and higher PASI score (p = 0.017) in psoriasis patients. After etanercept treatment, HADS-Depression (HADS-D) and HADS-Anxiety (HADS-A) scores were both decreased at M1, M3, and M6 (all p < 0.001) compared with M0. Most importantly, baseline depressed patients presented with a lower PASI 75 response rate at M3 (p = 0.014) and M6 (p = 0.005), and a reduced PASI 90 response rate at M6 (p = 0.045) compared with baseline non-depressed patients. Furthermore, multivariate logistic regression analyses revealed that depression symptoms at baseline were an independent predictive factor for the lower possibility of both PASI 75 response (p = 0.048) and PASI 90 response (p = 0.048) achievements at M6 in psoriasis patients. However, no correlation of baseline anxiety symptoms with PASI 75/90 responses was observed. Conclusion: Depression symptoms at baseline independently predict a worse clinical response to etanercept treatment in psoriasis patients.Keywords
This publication has 25 references indexed in Scilit:
- Depression Over Psoriasis: Assessment of associated Relief by addition of ADalimumab for the treatment of Psoriasis: Observational study (DORADO - Ps)Journal of Dermatology and Dermatologic Surgery, 2015
- Itch, disease coping strategies and quality of life in psoriasis patientsAdvances in Dermatology and Allergology, 2014
- Patient satisfaction with treatments for moderate-to-severe plaque psoriasis in clinical practiceBritish Journal of Dermatology, 2013
- Clinical practice guideline for an integrated approach to comorbidity in patients with psoriasisJournal of the European Academy of Dermatology and Venereology, 2012
- Depression, comorbidities and the TNF-α systemEuropean Psychiatry, 2008
- Etanercept Treatment for Children and Adolescents with Plaque PsoriasisNew England Journal of Medicine, 2008
- Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trialThe Lancet, 2006
- Psoriasis Is Common, Carries a Substantial Burden Even When Not Extensive, and Is Associated with Widespread Treatment DissatisfactionJournal of Investigative Dermatology Symposium Proceedings, 2004
- The depression, anxiety, life satisfaction and affective expression levels in psoriasis patientsJournal of the European Academy of Dermatology and Venereology, 2000
- The Hospital Anxiety and Depression ScaleActa Psychiatrica Scandinavica, 1983